Literature DB >> 24166908

Stressing the development of small molecules targeting HSP90.

Len Neckers1, Jane B Trepel.   

Abstract

Inhibitors of the molecular chaperone HSP90 have been in clinical development as anticancer agents since 1999. Recent clinical studies, including the work of Saif and colleagues in this issue of Clinical Cancer Research, demonstrate that significant progress has been made in overcoming the obstacles preventing regulatory approval. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24166908     DOI： 10.1158/1078-0432.CCR-13-2571

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  23 in total

1.  Chemical Perturbation of Oncogenic Protein Folding: from the Prediction of Locally Unstable Structures to the Design of Disruptors of Hsp90-Client Interactions.

Authors:  Antonella Paladino; Mark R Woodford; Sarah J Backe; Rebecca A Sager; Priyanka Kancherla; Michael A Daneshvar; Victor Z Chen; Dimitra Bourboulia; Elham F Ahanin; Chrisostomos Prodromou; Greta Bergamaschi; Alessandro Strada; Marina Cretich; Alessandro Gori; Marina Veronesi; Tiziano Bandiera; Renzo Vanna; Gennady Bratslavsky; Stefano A Serapian; Mehdi Mollapour; Giorgio Colombo
Journal:  Chemistry       Date:  2020-07-08       Impact factor: 5.236

Review 2.  Mechanistic Asymmetry in Hsp90 Dimers.

Authors:  Julia M Flynn; Parul Mishra; Daniel N A Bolon
Journal:  J Mol Biol       Date:  2015-04-03       Impact factor: 5.469

3.  Mutational Analysis of Glycogen Synthase Kinase 3β Protein Kinase Together with Kinome-Wide Binding and Stability Studies Suggests Context-Dependent Recognition of Kinases by the Chaperone Heat Shock Protein 90.

Authors:  Jing Jin; Ruijun Tian; Adrian Pasculescu; Anna Yue Dai; Kelly Williton; Lorne Taylor; Mikhail M Savitski; Marcus Bantscheff; James R Woodgett; Tony Pawson; Karen Colwill
Journal:  Mol Cell Biol       Date:  2016-01-11       Impact factor: 4.272

4.  Detecting Posttranslational Modifications of Hsp90.

Authors:  Rebecca A Sager; Mark R Woodford; Len Neckers; Mehdi Mollapour
Journal:  Methods Mol Biol       Date:  2018

5.  Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effects.

Authors:  Leah K Forsberg; Mercy Anyika; Zhenyuan You; Sean Emery; Mason McMullen; Rick T Dobrowsky; Brian S J Blagg
Journal:  Eur J Med Chem       Date:  2017-10-18       Impact factor: 6.514

Review 6.  The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma.

Authors:  Chi-Che Hsieh; Che-Hung Shen
Journal:  Curr Treat Options Oncol       Date:  2019-02-18

Review 7.  Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.

Authors:  Harvey Schwartz; Brad Scroggins; Abbey Zuehlke; Toshiki Kijima; Kristin Beebe; Alok Mishra; Len Neckers; Thomas Prince
Journal:  Cell Stress Chaperones       Date:  2015-06-13       Impact factor: 3.667

Review 8.  Regulation and function of the human HSP90AA1 gene.

Authors:  Abbey D Zuehlke; Kristin Beebe; Len Neckers; Thomas Prince
Journal:  Gene       Date:  2015-06-10       Impact factor: 3.688

9.  Involvement of cell surface 90 kDa heat shock protein (HSP90) in pattern recognition by human monocyte-derived macrophages.

Authors:  Małgorzata Bzowska; Anna Nogieć; Krystian Bania; Magdalena Zygmunt; Mirosław Zarębski; Jerzy Dobrucki; Krzysztof Guzik
Journal:  J Leukoc Biol       Date:  2017-05-26       Impact factor: 4.962

10.  Systematic Mutant Analyses Elucidate General and Client-Specific Aspects of Hsp90 Function.

Authors:  Parul Mishra; Julia M Flynn; Tyler N Starr; Daniel N A Bolon
Journal:  Cell Rep       Date:  2016-04-07       Impact factor: 9.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.